Cathie Wood, CEO of Ark Invest, has built a reputation for betting big on disruptive innovation. Among her high-conviction picks is Intellia Therapeutics (NTLA), a mid-cap biotech company that has caught the market’s attention with a 47% year-to-date gain. Fresh off a major regulatory win, the question now is whether the stock is poised for another leg up.
Intellia specializes in gene-editing therapies for rare diseases. Its pipeline features two lead candidates: lonvo-z, a treatment for hereditary angioedema (a rare condition causing painful swelling attacks), and nex-z, designed to treat transthyretin (ATTR) amyloidosis, a genetic disease that can lead to life-threatening cardiovascular complications.
Last year, the U.S. Food and Drug Administration (FDA) placed two phase 3 studies of nex-z on clinical hold after a patient death due to liver failure. But the agency has now lifted those holds, giving Intellia the green light to move forward. The news has provided a major catalyst, sending shares rebounding and extending 2025 gains to 47%.
Despite the upbeat development, investors may want to keep risk in check.
First, neither the company nor regulators have confirmed whether nex-z was responsible for the patient’s liver failure. Without that clarity, the possibility of recurring safety issues in future trials can’t be ruled out. Intellia has said it will exclude patients with certain liver conditions from future studies and will monitor for signs of liver inflammation more closely. Still, the unanswered question remains a lingering concern.
Second, gene-editing therapies face well-documented commercialization hurdles. They tend to be expensive, logistically complex to administer, and may face pushback from payers wary of covering high-cost, one-time treatments. Any lingering safety doubts would only make market adoption harder.
Then there’s the inherent volatility of biotech investing. Clinical setbacks and regulatory delays are par for the course, and any negative news could send shares tumbling just as quickly as they’ve risen.
That said, Intellia is not without its strengths. The company is developing nex-z in partnership with Regeneron, a heavyweight in the biotech space. And the market opportunity is significant: hundreds of thousands of patients worldwide suffer from ATTR amyloidosis, and unlike current chronic therapies, nex-z holds the potential to be a one-time curative treatment.
Intellia Therapeutics offers a compelling story in the fast-evolving gene-editing space, and the recent FDA decision removes a major overhang. Still, with unresolved safety questions and a challenging path to commercialization, the stock remains a high-risk, high-volatility play.
